Physician profile
Ambreen Mohamed
NPI 1437443637
$8,989.62
in general payments reported to CMS, 2019-2025
21 companies · $28.80 in 2025
The $28.80 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $72.57 · 2021: $889 · 2022: $90.72 · 2023: $7,766 · 2025: $28.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,325 · Travel and Lodging: $1,409 · Food and Beverage: $1,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,325.00 |
| Travel and Lodging | $1,409.09 |
| Food and Beverage | $1,060.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $6,964.82 | 2023 | Leqvio |
| Abbott Laboratories | $876.24 | 2021 | |
| Amgen INC. | $192.08 | 2022-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.32 | 2022-2023 | Jardiance |
| Amarin Pharma, INC. | $123.49 | 2023 | |
| W. L. Gore & Associates, INC. | $102.38 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.48 | 2020-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $66.66 | 2022-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $58.95 | 2019-2023 | Camzyos, Eliquis |
| Lexicon Pharmaceuticals, INC. | $46.31 | 2023 | Inpefa |
| Merck Sharp & Dohme LLC | $45.31 | 2023 | Verquvo |
| Novo Nordisk INC | $43.18 | 2023 | Ozempic, Wegovy, Saxenda |
| Lilly USA, LLC | $36.24 | 2023 | Mounjaro |
| Boston Scientific Corporation | $33.55 | 2021-2022 | |
| Bridgebio Pharma, INC. | $28.80 | 2025 | Attruby |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $26.26 | 2023 | Onpattro |
| Philips North America LLC | $25.94 | 2019 | |
| Scpharmaceuticals INC. | $23.32 | 2023 | |
| Inspire Medical Systems, INC. | $22.42 | 2023 | Inspire |
| Medtronic, INC. | $18.89 | 2023 | Corevalve Evolut R |
| Astrazeneca Pharmaceuticals LP | $17.98 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ambreen Mohamed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.